Dorsey Wright & Associates increased its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 48.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,189 shares of the company’s stock after buying an additional 710 shares during the quarter. Dorsey Wright & Associates’ holdings in argenex were worth $1,599,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the company. Abound Wealth Management increased its stake in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares during the period. Sound Income Strategies LLC acquired a new stake in argenex during the 4th quarter worth about $28,000. Whipplewood Advisors LLC purchased a new position in shares of argenex during the 1st quarter valued at about $28,000. Aventura Private Wealth LLC acquired a new position in shares of argenex in the 4th quarter valued at about $38,000. Finally, Sunbelt Securities Inc. purchased a new stake in shares of argenex in the third quarter worth about $36,000. 60.32% of the stock is owned by institutional investors and hedge funds.
argenex Trading Up 0.3%
ARGX stock opened at $860.55 on Friday. The company has a market cap of $53.52 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 1.06 and a beta of 0.45. argenex SE has a 12 month low of $560.91 and a 12 month high of $953.58. The firm has a 50-day moving average of $860.97 and a two-hundred day moving average of $813.59.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on ARGX. Royal Bank Of Canada lifted their target price on shares of argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Oppenheimer lowered their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Glj Research upgraded shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Wedbush reissued an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Thursday, June 11th. Finally, Weiss Ratings upgraded argenex from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,037.61.
Read Our Latest Stock Analysis on argenex
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
See Also
- Five stocks we like better than argenex
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
